LP-184 Rationale and design of two phase 3, Randomized, double-blind, placebo-controlled studies of the efficacy and safety of litifilimab in adults with active systemic lupus erythematosus: TOPAZ-1 and TOPAZ-2

LP-184 Rationale and design of two phase 3, Randomized, double-blind, placebo-controlled studies of the efficacy and safety of litifilimab in adults with active systemic lupus erythematosus: TOPAZ-1 and TOPAZ-2

Bibliographic Details
Main Authors: Richard A Furie, Kenneth Kalunian, Maria Dall’Era, Eric F Morand, Puja Joshi, Ting Wang, Xing Wei, Catherine Barbey, Ronald FVan Vollenhoven, Stacey Goode-sellers, George Kong, Youmna Lahoud
Format: Article
Language:English
Published: BMJ Publishing Group 2023-07-01
Series:Lupus Science and Medicine

Similar Items